SCHEMBL4160700

SCHEMBL4160700

O=C(O)C(OF)(c1ccccc1)c1ccc(F)c(F)c1F

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 9/20 0.37
CYP1A2 P05177 2/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
KCNE1 P15382 1/20 0.34
KCNQ1 P51787 1/20 0.34
CYP2C9 P11712 1/20 0.32
SLC22A12 Q96S37 1/20 0.31
ALDH1A1 P00352 2/20 0.31
ALOX15 P16050 1/20 0.31
HSD17B1 P14061 1/20 0.31
HSD17B2 P37059 1/20 0.31
KIF11 P52732 1/20 0.30
CYP2D6 P10635 1/20 0.30
HTT P42858 1/20 0.30
MCOLN3 Q8TDD5 1/20 0.30
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30097456 0.86 CES1 (0.38) KCNN4CYP1A2CES2CES1KCNE1
SCHEMBL4971512 0.82 KCNN4 (0.51) KCNN4CYP1A2CES2CES1KCNE1
SCHEMBL27768321 0.74 CYP2C9 (0.38) KCNN4CES2CES1KCNE1KCNQ1
SCHEMBL29101509 0.71 CYP3A4 (0.41) KCNN4CYP1A2CES2CES1KCNE1
SCHEMBL7413262 0.69 CES2 (0.43) KCNN4CES2CES1ALDH1A1KIF11
SCHEMBL28381845 0.69 KCNN4 (0.41) KCNN4KCNE1KCNQ1ALDH1A1KIF11
SCHEMBL29009844 0.66 CES2 (0.41) CYP1A2CES2CES1ALDH1A1KIF11
SCHEMBL9618644 0.66 CYP1A2 (0.48) KCNN4CYP1A2CES1CYP2C9ALDH1A1
SCHEMBL28223430 0.65 CES2 (0.39) CES2CES1ALDH1A1
SCHEMBL6904210 0.65 CA1 (0.32) KCNN4ALDH1A1ALOX15KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106279110-B heterocyclic compounds, medicaments containing said compounds, their use and processes for their preparation 勃林格殷格翰国际有限公司 2019-12-10 CN disclosed
US-20090054382-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2009-02-26 US disclosed
EP-1948167-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES, LTD. (IN) 2008-07-30 EP disclosed
WO-2007045980-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054382-A1 COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS PDE4B, PDE4A, PDE3B KCNN4 1875/4885CYP1A2 488/4885CES2 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.